356 related articles for article (PubMed ID: 12107555)
1. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
2. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions.
Mohamed F; Stuart OA; Sugarbaker PH
J Surg Res; 2003 Jul; 113(1):114-20. PubMed ID: 12943819
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.
Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y
J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780
[TBL] [Abstract][Full Text] [Related]
8. Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
Kamijo Y; Ito C; Nomura M; Sai Y; Miyamoto K
Cancer Lett; 2010 Jan; 287(2):182-6. PubMed ID: 19608331
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
de Bree E; Rosing H; Beijnen JH; Romanos J; Michalakis J; Georgoulias V; Tsiftsis DD
Anticancer Drugs; 2003 Feb; 14(2):103-10. PubMed ID: 12569296
[TBL] [Abstract][Full Text] [Related]
11. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
[TBL] [Abstract][Full Text] [Related]
12. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration.
Soma D; Kitayama J; Ishigami H; Kaisaki S; Nagawa H
J Surg Res; 2009 Jul; 155(1):142-6. PubMed ID: 19328496
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intraperitoneal gemcitabine in a rat model.
Pestieau SR; Stuart OA; Chang D; Jacquet P; Sugarbaker PH
Tumori; 1998; 84(6):706-11. PubMed ID: 10080682
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Loos WJ; Baker SD; Verweij J; Boonstra JG; Sparreboom A
Clin Pharmacol Ther; 2003 Oct; 74(4):364-71. PubMed ID: 14534523
[TBL] [Abstract][Full Text] [Related]
15. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].
Fushida S; Nao F; Kinami S; Ninomiya I; Fujimura T; Nishimura G; Ohta T; Yokogawa K; Miyamoto K; Miwa K
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1759-63. PubMed ID: 12402426
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of paclitaxel-containing liposomes in rats.
Fetterly GJ; Straubinger RM
AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
[TBL] [Abstract][Full Text] [Related]
18. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice.
Innocenti F; Danesi R; Di Paolo A; Agen C; Nardini D; Bocci G; Del Tacca M
Drug Metab Dispos; 1995 Jul; 23(7):713-7. PubMed ID: 7587959
[TBL] [Abstract][Full Text] [Related]
19. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor.
Li C; Newman RA; Wu QP; Ke S; Chen W; Hutto T; Kan Z; Brannan MD; Charnsangavej C; Wallace S
Cancer Chemother Pharmacol; 2000; 46(5):416-22. PubMed ID: 11127947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
